ReviewCells2025
Inflammation in Schizophrenia: The Role of Disordered Oscillatory Mechanisms.
Review in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review on dysconnectivity in face and emotion processing networks in schizophrenia.Cognitive, affective & behavioral neuroscience · 2026Pooled it
- The combined discriminative value of LHR, NLR, and platelet count in distinguishing first-episode schizophrenia.Annals of general psychiatry · 2026Article
- The predictive potential and relationship of peripheral non-enzymatic antioxidants with clinical symptoms in first-episode male adolescent-onset schizophrenia patients.Annals of general psychiatry · 2026Article
- Machine learning for oral frailty factors in hospitalized schizophrenia patients: two-stage feature selection and SHAP analysis.Frontiers in psychiatry · 2026Article
- Prevalence and influencing factors associated with the risk of malnutrition among long-term inpatients with schizophrenia in China.Frontiers in psychiatry · 2026Article
- Drug utilisation and adverse drug reaction monitoring in schizophrenic patients: A tertiary care hospital study in India.Bioinformation · 2026Article
- Alterations in serum IL-10 and IL-19 levels in drug-naïve first-episode adolescent-onset schizophrenia and their associations with clinical symptoms.Schizophrenia (Heidelberg, Germany) · 2025Article
- Evaluation of Inflammatory and Oxidative Markers and Their Diagnostic Value in Schizophrenia.Brain sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Schizophrenia is a chronic, debilitating disorder with diverse symptomatology, including disorganised cognition and behaviour. Despite considerable research effort, we have only a limited understanding of the underlying brain dysfunction. A significant proportion of individuals with schizophrenia exhibit high levels of inflammation, and inflammation associated with maternal immune system activation is a risk factor for the disorder. In this review, we outline the potential role of inflammation in the disorder, with a particular focus on how cytokine release might affect the development and function of GABAergic interneurons. One consequence of this change in inhibitory control is a disruption in oscillatory processes in the brain. These changes disrupt the spatial and temporal synchrony of neural activity in the brain, which, by disturbing representations of time and space, may underlie some of the disorganisation symptoms observed in the disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.